HealthPhoto: Deccan HeraldIndia Sees Surge in Semaglutide Use and Emerging Lawsuits
After Novo Nordisk’s semaglutide patent expired in March, Indian companies launched cheaper versions, causing semaglutide sales to jump from 25,000 units in February to 1.7 lakh units in April. Overall GLP-1 injectable sales rose 76% to 4.14 lakh units in April. The market grew to Rs 2,333 crore in 12 months. However, increased use has led to emerging litigation in Indian courts similar to Western markets.
Deccan Herald·


